News | Mammography | April 29, 2025

iCAD collaborates with Microsoft to offer radiology providers the option for automated patient reporting on mammography results through PowerScribe integration.

iCad, Microsoft to Collaborate

April 29, 2025 — iCAD, a global provider of clinically proven AI-powered cancer detection solutions, has announced a collaboration with Microsoft, to include a set of AI-powered mammography solutions in iCAD’s ProFound Breast Health Suite on Microsoft’s Precision Imaging Network. The iCAD and Microsoft collaboration provides access to automated radiology mammography reporting for patients through Microsoft’s advanced radiology reporting platform, PowerScribe. iCAD’s ProFound AI Breast Health Suite will be fully cloud-hosted across Microsoft’s extensive network, providing radiologists and healthcare providers with streamlined, AI-driven insights that help to elevate breast health detection, enhance clinical workflows, and ultimately aim to improve patient outcomes.

Many radiologists across the U.S. rely on PowerScribe, for its AI-based radiology reporting and workflow capabilities. As a mammography solution offered through Precision Imaging Network, iCAD will be uniquely optimized for integration within PowerScribe to enable radiologists to efficiently create, review, and share diagnostic reports, leveraging features that standardize language and automate routine tasks. Precision Imaging Network securely hosts third-party AI models with standardized integrations into radiology workflows.

“We are excited to partner with Microsoft to expand access to our AI solutions for breast cancer detection across a broader network of healthcare providers,” said Dana Brown, CEO and president of iCAD. “This collaboration supports our growth strategy by expanding the reach of our industry-leading technology, driving deeper market penetration, and advancing our transition to a SaaS model. Integrating ProFound AI results in the PowerScribe report aligns with our shared mission to improve cancer detection and care while empowering radiologists to deliver earlier, more accurate interpretations with greater confidence and efficiency.”

“With the integration of iCAD’s ProFound suite of breast health offerings with our Precision Imaging Network and PowerScribe solutions, we will help provide radiologists and patients with more accurate, actionable breast health insights, while streamlining mammography screening workflow, driving clinical and operational value at scale.” said Vikram Chhabra, general manager, Diagnostic Solutions at Microsoft.

Precision Imaging Network provides streamlined access to a curated collection of third-party AI models through a single point of integration, empowering radiologists and healthcare systems to leverage AI insights directly within existing clinical workflows. Connecting over 17,000 healthcare facilities nationwide, Precision Imaging Network seamlessly integrates iCAD’s ProFound AI® technology, making it readily available to radiologists and specialty physicians across diverse healthcare environments. By embedding iCAD’s capabilities in cancer detection and density assessment, Precision Imaging Network delivers targeted, patient-specific insights with unprecedented efficiency.

This collaboration follows recent FDA clearance of iCAD’s ProFound Detection Version 4.0 for Digital Breast Tomosynthesis (DBT), marking a new era in AI-powered breast cancer detection. This fourth-generation AI solution utilizes advanced deep learning convolutional neural networks, achieving a 22% improvement in detecting complex and aggressive cancer subtypes over previous versions, with significant enhancements for dense breast tissue. ProFound Detection Version 4.0 is specifically designed to navigate the intricacies of DBT exams, achieving an 18% reduction in lesion markings to minimize potential false positives and streamline radiologists’ workflows. The solution also incorporates priors into the AI analysis, allowing radiologists to better assess changes over time, further supporting more accurate, personalized patient screening assessments.

iCAD will showcase this next-generation AI collaboration, along with its end-to-end breast health AI suite and the recently cleared ProFound Detection Version 4.0, at the upcoming 2025 SIIM25 Annual Meeting + InformaticsTECH Expo in Portland, May 21-23. 

For more information, including the latest in regulatory clearances, please visit www.icadmed.com.


Related Content

News | Mammography

April 24, 2025 — GE HealthCare will feature its latest advancements in diagnostic accuracy and patient-centered breast ...

Time April 24, 2025
arrow
News | Artificial Intelligence

March 10, 2025 — Lunit, a provider of AI-powered solutions for cancer diagnostics and therapeutics, has published a ...

Time March 10, 2025
arrow
News | Artificial Intelligence

Feb. 19, 2025 — SimonMed Imaging and HeartLung Technologies have signed a strategic partnership to offer HeartLung's AI ...

Time March 04, 2025
arrow
News | Ultrasound Imaging

Jan. 28, 2025 — GE HealthCare recently announced it has received 510(k) clearance from the United States Food and Drug ...

Time January 29, 2025
arrow
News | Breast Imaging

Jan. 8, 2025 — ScreenPoint Medical has acquiredf Biomediq A/S, a research-based company focused on the research ...

Time January 10, 2025
arrow
News | Breast Imaging

Dec.11, 2024 — iCAD, Inc., a provider of clinically proven AI-powered cancer detection solutions, recently announced ...

Time December 18, 2024
arrow
News | Mammography

Dec. 5, 2024 — At RSNA 2024, Lunit and Volpara Health announced their unified vision, focusing on a comprehensive ...

Time December 05, 2024
arrow
News | Mammography

Nov. 26, 2024 — GE HealthCare has introduced the Pristina Via* mammography system designed to enhance the screening ...

Time December 02, 2024
arrow
News | Artificial Intelligence

Dec. 2, 2024 — Lunit recently unveiled follow-up findings from the ScreenTrustCAD trial. This study, conducted at Capio ...

Time December 02, 2024
arrow
News | Mammography

Sept. 30, 2024 — Siemens Healthineers recently announced the Food and Drug Administration’s premarket approval (PMA) for ...

Time September 30, 2024
arrow
Subscribe Now